{"id":42596,"date":"2018-12-20T17:40:23","date_gmt":"2018-12-20T15:40:23","guid":{"rendered":"https:\/\/newserver.fyb.de\/shs-invests-in-swiss-life-science-company-evitria\/"},"modified":"2018-12-20T17:40:23","modified_gmt":"2018-12-20T15:40:23","slug":"shs-invests-in-swiss-life-science-company-evitria","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/","title":{"rendered":"SHS invests in Swiss life science company evitria"},"content":{"rendered":"

<\/b>T\u00fcbingen\/Schlieren (Switz\u00ader\u00adland) - SHS<\/strong> V, a fund mana\u00adged by T\u00fcbin\u00adgen-based SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment<\/strong>, is inves\u00adt\u00ading in Swiss evitria<\/strong> AG toge\u00adther with AFINUM<\/strong>. The life science company supplies large phar\u00admaceu\u00adti\u00adcal and biotech compa\u00adnies with custom anti\u00adbo\u00addies for rese\u00adarch. For SHS, it is the first invest\u00adment from the SHS V fund, which had its first closing in July 2018.
\n
\n<\/b>evitria AG, based in Schlie\u00adren near Zurich, is a service provi\u00adder for the produc\u00adtion of custo\u00admi\u00adzed anti\u00adbo\u00addies. The company has a track record of more than 5,000 anti\u00adbody-based mole\u00adcu\u00adles produ\u00adced. evitria\u2019s custo\u00admers are leading global phar\u00admaceu\u00adti\u00adcal compa\u00adnies as well as acade\u00admic labo\u00adra\u00adto\u00adries and biotech compa\u00adnies from North America, Europe, Asia and Australia.<\/p>\n

Many of the worl\u00add\u2019s top-selling drugs are thera\u00adpeu\u00adtic anti\u00adbo\u00addies. Accor\u00addin\u00adgly, drug deve\u00adlo\u00adpers are inten\u00adsi\u00advely rese\u00adar\u00adching further anti\u00adbody-based drugs against dise\u00ada\u00adses such as cancer or neuro\u00adlo\u00adgi\u00adcal disor\u00adders such as demen\u00adtia. For this, they need specia\u00adli\u00adzed and relia\u00adble suppli\u00aders. The market in which evitria opera\u00adtes will ther\u00ade\u00adfore conti\u00adnue to grow dyna\u00admi\u00adcally in the coming years.<\/p>\n

SHS and AFINUM acquire a stake in evitria AG, which was foun\u00added in 2010, with the aim of tapping into new custo\u00admer groups and estab\u00adli\u00adshing a busi\u00adness unit in the USA to serve the market there directly. This is the first joint invest\u00adment for SHS and AFINUM.<\/p>\n

Corne\u00adlius Maas, Senior Invest\u00adment Mana\u00adger at SHS, says: \u201cWe are very plea\u00adsed to join forces with AFINUM and the expe\u00adri\u00aden\u00adced manage\u00adment team to further deve\u00adlop this fast-growing company inter\u00adna\u00adtio\u00adnally. The anti\u00adbody produc\u00adtion process at evitria is charac\u00adte\u00adri\u00adzed by high effi\u00adci\u00adency, quality and stabi\u00adlity combi\u00adned with very short deli\u00advery times. In short, evitria combi\u00adnes an estab\u00adlished, leading market posi\u00adtion with high growth poten\u00adtial. These charac\u00adte\u00adristics guide all further invest\u00adments of our SHS\u2011V fund.\u201d<\/p>\n

About SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment mbH
\n<\/b>T\u00fcbin\u00adgen-based SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment invests in medi\u00adcal tech\u00adno\u00adlogy and life science compa\u00adnies with a focus on expan\u00adsion finan\u00adcing, share\u00adhol\u00adder chan\u00adges and succes\u00adsion situa\u00adtions. In doing so, SHS enters into both mino\u00adrity and majo\u00adrity share\u00adhol\u00addings. As an expe\u00adri\u00aden\u00adced indus\u00adtry inves\u00adtor, the company, which was foun\u00added in 1993, supports the growth of its port\u00adfo\u00adlio compa\u00adnies through a network of colla\u00adbo\u00adra\u00adti\u00adons, for exam\u00adple in the intro\u00adduc\u00adtion of new products, regu\u00adla\u00adtory issues or entry into addi\u00adtio\u00adnal markets. The German and inter\u00adna\u00adtio\u00adnal inves\u00adtors in SHS funds include profes\u00adsio\u00adnal pension funds, pension funds, stra\u00adte\u00adgic inves\u00adtors, funds of funds, family offices, entre\u00adpre\u00adneurs and the SHS manage\u00adment team. The equity invest\u00adment of the AIFM-regis\u00adtered company is up to \u20ac 30 million, volu\u00admes excee\u00adding this can be imple\u00admen\u00adted with a network of co-inves\u00adtors. Follo\u00adwing the first closing of SHS\u2019s fifth fund of more than EUR 90 million in July 2018, invest\u00adments are alre\u00adady being made from the fund. The final closing will take place in July 2019.<\/p>\n

www.shs-capital.eu<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

T\u00fcbingen\/Schlieren (Switz\u00ader\u00adland) \u2014 SHS V, a fund mana\u00adged by T\u00fcbin\u00ad\u00adgen-based SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment, is inves\u00adt\u00ading in Swiss evitria AG toge\u00adther with AFINUM. The life science company supplies large phar\u00admaceu\u00adti\u00adcal and biotech compa\u00adnies with custom anti\u00adbo\u00addies for rese\u00adarch. For SHS, it is the first invest\u00adment from the SHS V fund, which had its first closing [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42611,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42596","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-venture-capital-news"],"yoast_head":"\nSHS invests in Swiss life science company evitria - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHS invests in Swiss life science company evitria - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"T\u00fcbingen\/Schlieren (Switz\u00ader\u00adland) - SHS V, a fund mana\u00adged by T\u00fcbin\u00adgen-based SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment, is inves\u00adt\u00ading in Swiss evitria AG toge\u00adther with AFINUM. The life science company supplies large phar\u00admaceu\u00adti\u00adcal and biotech compa\u00adnies with custom anti\u00adbo\u00addies for rese\u00adarch. For SHS, it is the first invest\u00adment from the SHS V fund, which had its first closing […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-20T15:40:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"SHS invests in Swiss life science company evitria\",\"datePublished\":\"2018-12-20T15:40:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\"},\"wordCount\":459,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\",\"url\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\",\"name\":\"SHS invests in Swiss life science company evitria - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg\",\"datePublished\":\"2018-12-20T15:40:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg\",\"width\":512,\"height\":512},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHS invests in Swiss life science company evitria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHS invests in Swiss life science company evitria - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/","og_locale":"en_US","og_type":"article","og_title":"SHS invests in Swiss life science company evitria - FYB Financial Yearbook","og_description":"T\u00fcbingen\/Schlieren (Switz\u00ader\u00adland) - SHS V, a fund mana\u00adged by T\u00fcbin\u00adgen-based SHS Gesell\u00adschaft f\u00fcr Betei\u00adli\u00adgungs\u00adma\u00adnage\u00adment, is inves\u00adt\u00ading in Swiss evitria AG toge\u00adther with AFINUM. The life science company supplies large phar\u00admaceu\u00adti\u00adcal and biotech compa\u00adnies with custom anti\u00adbo\u00addies for rese\u00adarch. For SHS, it is the first invest\u00adment from the SHS V fund, which had its first closing […]","og_url":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-12-20T15:40:23+00:00","og_image":[{"width":512,"height":512,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"SHS invests in Swiss life science company evitria","datePublished":"2018-12-20T15:40:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/"},"wordCount":459,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/","url":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/","name":"SHS invests in Swiss life science company evitria - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg","datePublished":"2018-12-20T15:40:23+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-shs.jpg","width":512,"height":512},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/shs-invests-in-swiss-life-science-company-evitria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"SHS invests in Swiss life science company evitria"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42596"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42596\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42611"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}